IQVIA’s Post

This is an excellent article from Andy highlighting the fact that 'willingness to change' is critical to see what JAPAC as a region offers to getting clinical trials onto the next gear for sponsors!

Trial start-up sets the pace for everything that follows in clinical development. As studies become increasingly complex, efficient site activation is becoming a critical factor in delivering timelines. Andy Lee, Head of Site Activation, Asia, examines how different JAPAC markets approach site activation and why understanding country-specific strengths matters when planning clinical development programs. Read the blog to learn why treating JAPAC as a single geography may mean overlooking important opportunities: https://lnkd.in/eXqwDRuB

One thing I have noticed working with biotech companies in the US and Europe: Japan is often simply not on the clinical development map. It is not necessarily a conscious decision to exclude Japan. It is more that Japan tends to come up much later, after the global development strategy has already been defined. But does it have to be that way? I’m looking forward to discussing this on October 20 with Koji Shinozaki and Hiroki Matsushima — particularly how Japan can be considered earlier as part of global clinical development, and what would make that practical for biotech companies. Hope you can join us! Strengthening Global Clinical Development Through Early Integration of Japan October 20, 2026 | 12:00 PM ET | Online Event details & registration: https://lnkd.in/p/g_S-kEJ2 #ClinicalDevelopment #Biotech #Japan #DrugDevelopment

I was taught never to use the word “obvious.” If something truly is obvious, saying so is redundant. And if it is not obvious to everyone, calling it “obvious” can be presumptuous. Despite that, I will say that connecting Australia’s and Southeast Asia’s life sciences ecosystems has obvious benefits. Or does it? I’m looking forward to joining my colleagues Siew Mien Chao and Pramod Kashid for this discussion, where we’ll explore where greater collaboration between Australia and Southeast Asia can create real value for both ecosystems. Big thank you to Zhengdao Hideyoshi Du (ChMPP) and Expecto Health Science and the LifeSciences Australia for putting this together!

From strengthening connections across Asia-Pacific to putting those connections into practice. Last month, we introduced Zhengdao Hideyoshi Du (ChMPP) through our Member Spotlight series and shared his passion for building stronger connections between Australia and Asia’s life sciences communities. That same focus is behind an upcoming LifeSciences Australia webinar, hosted by Hideyoshi: How Southeast Asia Can Complement Australia in Clinical Trials: What Sponsors, CROs, and Sites Need to Win More Regional Studies On 8 September, the webinar will bring together three speakers with regional experience to explore how Australia and Southeast Asia can build on their respective strengths to support greater regional clinical trial activity. Joining the discussion: 🔹 Siew Mien Chao, Director, Clinical Research & Innovation Office, Tan Tock Seng Hospital 🔹 Dr Pramod Kashid, Co-Founder & CEO, Expecto Health Science 🔹 Martin Lim, Co-Founder & CEO, ONWARD Health Research Hosted by Zhengdao Hideyoshi Du (ChMPP), the conversation will consider what stronger regional collaboration could look like in practice, and what sponsors, CROs and sites need to attract and successfully deliver more regional studies. 📅 Tuesday 8 September 2026 🕧 12.30 pm – 1.30 pm AEST 💻 Online + Free to Attend It’s also a great example of how our members contribute their experience, connections and perspectives to help shape conversations across the LifeSciences Australia community. Registration details are in the comments below. #LifeSciencesAustralia #ClinicalResearch #ClinicalTrials #AsiaPacific #SoutheastAsia #MemberSpotlight

The Global Clinical Trial Race: Who Is Gaining Ground and Why? Clinical research did not simply move from the US to China. The real shift is more surprising: US sponsors still lead, China is accelerating, and Europe has lost the most ground. The map follows speed, predictability, and execution. Your start-up time is key in your strategy. #ClinicalResearch #ClinicalTrials #ResearchStrategy #DocNa

Clinical trial complexity continues to rise, placing greater pressure on study start-up and execution. In his latest article, Andy Lee explores how different JAPAC markets are addressing this challenge through established activation pathways, experienced sites, regulatory evolution, and strong investigator networks. Drawing on regional insights and country-specific examples, he examines how speed, patient access and operational efficiency intersect across JAPAC, and why sponsors may benefit from considering the region earlier in their development planning. Read the article here: https://lnkd.in/ePZwseiB

Thailand's next competitive edge won't come from potential alone. It will come from coordination. On 7 September, leaders from government, regulators, research and industry came together at the PReMA – Health Systems Research Institute Policy Dialogue Forum with one shared question: How can we turn Thailand’s clinical research strengths into a coordinated national roadmap for action? Thailand already has the foundations. The next step is connecting the ecosystem end to end—turning strengths in research, policy and industry into greater investment and impact. A stronger clinical research ecosystem means faster access to innovation, greater research capabilities and stronger long-term competitiveness. This is what collaboration looks like when an ecosystem decides to move as one – from dialogue to roadmap, and from potential to action. #PReMA #TrustedHealthcarePartner #HealthForwardThailand

The Asia Pacific region has a diverse clinical research landscape which calls for a patient-centric approach. In our newest article, explore how tailored trial design and local expertise can help Sponsors improve recruitment, retention, and trial success: https://bit.ly/4xPFExk

Are you prepared for the new demands shaping clinical development and trial delivery? Discover how technology-enabled insights and stronger site partnerships are reshaping trial delivery, helping sponsors accelerate study timelines and enhance trial execution. Hear from Leanne Magne from the IQVIA Workshop during DIA China 2026 and explore what's needed to move studies forward with greater confidence. Connect with IQVIA today to continue the conversation: https://lnkd.in/ehp_5H2V